Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Kisspeptin-10 | PT-141 (Bremelanotide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation. | Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. |
| Timing | Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity. | 45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response. |
| Cycle Duration | Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis. | As-needed basis. Not intended for daily use. |
| Evidence Level | moderate_human | strong_human |
Kisspeptin-10 is the 10-amino acid C-terminal fragment of the kisspeptin family that signals directly to GnRH neurons through the kisspeptin receptor (KISS1R/GPR54), triggering GnRH release into the portal circulation. This stimulates LH and FSH secretion from anterior pituitary gonadotrophs. In men, intravenous kisspeptin-10 produces rapid dose-dependent LH rises (4.1 to 12.4 IU/L at 1 mcg/kg within 30 minutes), increases LH pulse frequency and amplitude, and subsequently elevates testosterone through the HPG axis.
Research indicates 1-10 mcg/kg via subcutaneous injection or IV bolus for acute HPG axis stimulation.
Morning dosing preferred for testosterone optimization. Can be used acutely before sexual activity.
Short-term use only. Continuous kisspeptin administration may cause tachyphylaxis (desensitization) of the HPG axis.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.
Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
As-needed basis. Not intended for daily use.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →